Description
Product details
DAPA VILDA 5/100 SR Dapagliflozin (5mg), Vildagliptin SR (100mg) DAPA VILDA 5/100 SR is a combination medication consisting of two active ingredients: Dapagliflozin (5mg) and Vildagliptin SR (100mg). Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor, while Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor with sustained-release formulation. Dapagliflozin works by inhibiting SGLT2 in the kidneys, thereby reducing glucose reabsorption and increasing urinary glucose excretion, leading to lower blood glucose levels. Vildagliptin, on the other hand, acts by inhibiting DPP-4 enzyme, which prolongs the action of incretin hormones like GLP-1 and GIP, enhancing insulin secretion and suppressing glucagon release, ultimately reducing blood glucose levels. This combination medication is indicated for the management of type 2 diabetes mellitus in adults. By targeting different pathways involved in glucose metabolism, DAPA VILDA 5/100 SR offers a comprehensive approach to glycemic control, helping patients achieve and maintain target blood glucose levels. It is typically prescribed as an adjunct to diet and exercise in patients whose diabetes is not adequately controlled with monotherapy or as a dual therapy option for those who require additional glucose-lowering agents. As with any medication, DAPA VILDA 5/100 SR may cause side effects, including but not limited to urinary tract infections, genital mycotic infections, hypoglycemia, and gastrointestinal disturbances. Patients should be monitored regularly for these adverse effects, and dosage adjustments may be necessary based on individual response and tolerability. Overall, DAPA VILDA 5/100 SR offers a convenient once-daily dosing option and a synergistic approach to managing type 2 diabetes, helping patients achieve better glycemic control and potentially reducing the risk of long-term complications associated with uncontrolled diabetes. However, it should only be used under the supervision of a healthcare professional and as part of a comprehensive diabetes management plan tailored to the individual patient's needs and goals. For further information: EMAIL: info@sterispharma.com / contact@sterispharma.com CALL/WHATSAPP: 7877551268, 7849827488 Order Now https://www.sterisonline.com/product/dapa-vilda-5-100-sr-134362